Real estate is the next big catalyst for marijuana stocks in 2017, as more voters demand legalized recreational and medical cannabis in their states.
A comprehensive study slams many of the alleged benefits of marijuana and points to serious negative effects. What will the impact of this study be for marijuana stocks?
Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.
Most myths have at least a little bit of truth interspersed with a lot that is false. That’s the case with these three myths about marijuana stocks that some might mistakenly believe.
CanniMed Therapeutics Inc. became the latest and last medical marijuana company Thursday to go public in 2016, capping off a banner year in the burgeoning sector.
Here are three stocks that have doubled investors’ money in 2016, and a look into whether or not they can continue to rally in 2017.
In the last few months, the medical marijuana growers have dominated the trading activity on the TSX Venture in terms of dollar volume almost exclusively, belying a persistent interest from investors in Canada and the United States.
Canopy, previously listed on the Canadian Venture Exchange under stock symbol TWD (Tweed was the original company, later consolidated into Canopy), began trading publicly on the Toronto Stock Exchange in July amid great anticipation from investors and financial markets.
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
MassRoots Inc is a penny play in the cannabis space on the technology side that has been performing extremely well of late on several key catalysts.
The fed’s report was largely positive for the recreational marijuana industry when it was released Tuesday. Aurora Cannabis stock was one of the biggest pot stock beneficiaries of the announcement, but has since had a regression in share price.
Pot stocks got a lift Tuesday following the issue of a task force report with recommendations on recreational pot sales.
Let’s take a look back on this past year and see what the future holds for marijuana stocks.
According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.
With several states passing measures to legalize marijuana in 2016, the cannabis business looks poised to finally to take off. But for investors, there remains a quandary: How do you find a way to get in on the ground floor of this new growth industry?
On Nov. 21, 2016, Kaya Holdings (OTCQB:KAYS), whose subsidiary Kaya Shack opened its first cannabis dispensary in Portland, Oregon, in 2014, announced that it had filed its third quarterly report of 2016, reporting a 700% year-over-year revenue increase.
Creso Pharma shares jumped when the medical cannabis company debuted on the ASX. The shares are up by a quarter since listing on Thursday at 25 cents.
New Cannabis Ventures broke the news Monday evening. It will be the first publicly-traded cannabis-related Real Estate Investor Trust or REIT and, if approved, would be the first cannabis company to be traded at the venerable NYSE.
For investors, the rising prospects of legalized pot may be too good to pass up, yet the publicly traded cannabis companies may not be such a smart bet.
On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.
On Sept. 26, 2016, Massroots (OTCQB:MSRT) issued a letter from Isaac Dietrich, Chairman and Chief Executive Officer, on the company’s outlook for Fall 2016, including updates on the product pipeline, user growth and expense reductions, among others; however, the letter failed to address the company’s recent default on debt.
GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.
Shares of Insys Therapeutics Inc. (NASDAQ:INSYS) soared 19% in premarket trade Tuesday.
There have been some developments in a handful of cannabis related companies in the past few days.
Federal securities regulators have filed a complaint against Bruce Perlowin that charges the CEO of publicly-traded Hemp Inc of committing a long-running fraud by evading securities registration provisions and selling hundreds of millions of unregistered shares.
On April 28, 2016, the U.S. Securities and Exchange Commission announced the temporary suspension of trading in Pineapple Express (OTC: PNPL) due to unusual market activity in the company’s securities. The suspension started at 9:30 a.m. EDT today and will end at 11:59 p.m. EDT on May 11.
MassRoots, Inc., the ‘Facebook’ for cannabis consumers, is filing an offering to go public with hopes that the NASDAQ will approve them for a listing.
The marijuana industry may be growing rapidly, but if you don’t know these critical points, your investment in marijuana stocks could go up in smoke.
On March 14, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for the first pivotal Phase 3 study of Epidiolex, a CBD-based medicine, in treating Dravet syndrome, a severe form of pediatric epilepsy.
Chris Bunka, the CEO and Chair at Lexaria Corp. (CSE: LXX) (OTCQB: LXRP), suspects that market-makers and broker-dealers are engaged in something potentially illegal and certainly untoward in connection with the stock of the company.
Viridian Capital Advisors today released its 2015 Cannabis Industry Report and Stock Index.
While there has been a significant victory in Oregon to open up delivery services and challenges to the status quo are taking place in banking, the most promising development for everyday investors is the ongoing effort to open up the public markets to marijuana firms.
Randy Shipley, the founder and CEO of CannaFundr.com, is among those who believe that the new SEC rules will “potentially” have a positive influence on the marijuana industry.
Zynerba presented the status of its research program at BIO Investor Forum. This is a 14-year-old annual biotech gathering, with roughly 600 attendees from 21 countries, and the presentation, in San Francisco, looked likely to be a big event in this company’s development.
It has been a bit of a dry spell for decent IPOs in the cannabis space. But the rains have come down with the initial public offering of Devon, Pennsylvania-based Zynerba Pharmaceuticals (NASDAQ: ZYNE).
On July 9, 2015, the Securities and Exchange Commission announced that it had settled charges against Alexander Hawatmeh and Christopher Mrowca. So far, so good, but is the legal marijuana industry any safer for investors?
There is no profit without risk, and it is well for those who would invest in this field, either capital or entrepreneurial energy or both, that they recognize the risk.
Last Wednesday, two pain specialists that were top subscribers of Insys Therapeutics’ (NASDAQ: INSY) leading prescription therapy Subsys were arrested, as part of a year-long operation by the DEA.
Oxis Biotech, a subsidiary of Oxis International (OTCQB: OXIS), recently filed a notification to shareholders and the SEC that the company would be entering into a reverse split of not less than 1-50 shares and not more than 1-250 shares.
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.
Stocks started out with a positive bias, but the early bullishness waned as the day continued. Cannabis stocks started the week dragging. Apparently, they had a case of the Mondays.
Cannabis stocks struggled on this Friday trading session. Volumes were low, profit taking in recent high flyers, and poor trading behavior to cap out the week.
Cannabis stocks traded lightly with a positive bias. The 4/20 holiday is now behind us, 10ks are done, so cannabis traders and investors are looking toward the next potential catalyst. In the coming weeks, we will get a look at 10Qs for Q1.
News flow was very light in the cannabis sector, which is not very surprising given the day of the week. As a result, volumes were very low and prices mixed.
The cannabis sector welcomed the successful introduction of MassRoots (OTCQB: MSRT), with shares traded comfortably above $1 with great volume.
The conference circuit is starting to heat up again as several public companies will be attending and speaking at conferences around the country for the remainder of the month.
If one were to ask what health and food safety have to do with cannabis, the answer is a lot! Hemp is a vital part of the cannabis industry.
MassRoots, which will begin trading on or around April 9, 2015, under the ticker MSRT, is set to be the first public cannabis company with a revenue model and a customer acquisition strategy built entirely around social media platforms.
One of the best parts of being a cannabis investor is being able to witness history in the making on a daily basis. This time it is the announcement of the first cannabis tech IPO with MassRoots (OTC Pink: MSRT) preparing to come online this month.
Public stock investors in the cannabis industry are largely relegated to the over-the-counter marketplace. This is much different from stocks trading on an exchange, and far less expensive for companies to access.